Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.

导出原文传递

翻译打印收藏纠错

第一作者： Yuichi,Koda

第一单位： Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.

作者： Yuichi,Koda ^[1] ; Kozo,Kuribayashi ^[2] ; Hiroshi,Doi ^[3] ; Kazuhiro,Kitajima ^[3] ; Yasuhiro,Nakajima ^[1] ; Hirotoshi,Ishigaki ^[1] ; Akifumi,Nakamura ^[4] ; Toshiyuki,Minami ^[1] ; Ryo,Takahashi ^[1] ; Takashi,Yokoi ^[5] ; Takashi,Kijima ^[5]

作者单位： Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan. ^[1] Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, kuririn@hyo-med.ac.jp.;Department of Thoracic Oncology, Hyogo College of Medicine, Nishinomiya, Japan, kuririn@hyo-med.ac.jp. ^[2] Department of Radiology, Hyogo College of Medicine, Nishinomiya, Japan. ^[3] Division of Thoracic Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan. ^[4] Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.;Department of Thoracic Oncology, Hyogo College of Medicine, Nishinomiya, Japan. ^[5]

关键词 Gemcitabine Irinotecan Malignant pleural mesothelioma Second-line treatment